# KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

> **NCT04601610** · PHASE1,PHASE2 · TERMINATED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 6 (actual)

## Conditions studied

- Advanced HCC

## Interventions

- **DRUG:** KN046 （PD-L1/CTLA4 BsAb）
- **DRUG:** Ningetinib Tosylate（multi-target TKI）

## Key facts

- **NCT ID:** NCT04601610
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-07
- **Primary completion:** 2022-05-30
- **Final completion:** 2022-05-30
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The sponsor's development strategy adjustment resolution is terminated
- **Last updated:** 2022-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04601610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04601610, "KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04601610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*